Q2 2026 revenue rose 14.9% year-over-year to $390 million, with strong growth in both thrombectomy and embolization/access products, especially in the U.S. Net income declined due to higher taxes and operating expenses. The company announced a $14.5 billion merger with Boston Scientific, expected t…
Q2 2026 revenue rose 14.9% year-over-year to $390 million, with strong growth in both thrombectomy and embolization/access products, especially in the U.S. Net income declined due to higher taxes and operating expenses. The company announced a $14.5 billion merger with Boston Scientific, expected to close by year-end 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
